Pharmaceutical Litigation
Cylert®
Manufacturer:
Abbott Laboratories
Uses: Used to treat attention-deficit problems.
More Information
Attention deficit drug being pulled from market
Maker doesn't address charges of liver failure
 |
| Cylert |
Reuters News Service
WASHINGTON - Abbott Laboratories said Thursday it was halting sales of a 30-year-old attention deficit drug that a consumer group complained was too dangerous to stay on the market.
Abbott decided to discontinue the drug, Cylert, because of declining sales, Abbott spokeswoman Melissa Brotz said. The drug's sales this year will be less than $1 million, she said.
Brotz declined to comment on charges made earlier Thursday from consumer
group Public Citizen that the drug had caused 21 cases of liver failure,
including 13 that were fatal or required transplants.
"We're in the process of discontinuing it ... but that's because of declining
usage and sales and because there are generics available," Brotz said.
Generic companies sell copycat versions of the drug under the name pemoline.
Public Citizen asked the U.S. Food and Drug Administration on Thursday to ban
Cylert and its generic competitors immediately. Generic companies can still sell
their versions even after Abbott pulls the medicine, unless the FDA determines
the drug was withdrawn for safety reasons.
A petition from Public Citizen said Britain and Canada already had pulled the
drug off the market, while the FDA opted to strengthen warnings twice and allow
sales to continue.
The warnings failed to increase doctors' monitoring of liver function in
patients treated with pemoline, which offers no benefit over other therapies,
the group said.
"In light of this evidence of unique liver toxicity without evidence of
unique therapeutic benefit, we contend that the only responsible course of
action is to remove this dangerous drug from the market," Public Citizen said.
Cylert is a stimulant that was approved to treat attention deficit
hyperactivity disorder, or ADHD, in 1975. Last year, about 117,000 prescriptions
for the drug were filled in the United States, according to Public Citizen.
FDA spokeswoman Susan Cruzan said the agency would carefully review the
petition, which also was signed by Dr. Fredric Solomon, a psychiatrist and ADHD
specialist at the George Washington University School of Medicine.
Public Citizen has filed several petitions with the FDA seeking to have
various drugs withdrawn.
Earlier this month, the FDA denied a petition from Public Citizen asking for
a ban on AstraZeneca's cholesterol treatment Crestor.
For more information:
Pharmaceutical Litigation
Prescription
Injury FAQs
Pharmaceutical Legal Glossary
|
